An article authored by Jonathan Roses titled “Best Practices for Orange Book Listings” was published in The Pharma Letter as an “Expert View.” In this article, Jon provides insights into how to successfully navigate the complexities of the US Food and Drug Administration’s Orange Book. He sets the stage for where we are today and best practices for new drug application holders assessing which patents they should list in the Orange Book. Read more.
